{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":15,"n_cols":5,"rows_kept":15,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[4,2,4,3],[5,2,5,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[13,2,13,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910790451003321"]
[null,null,"Titolo",null,"Multiple myeloma [[electronic resource] ] : a new era of treatment strategies / / editors, Klaus Podar, Kenneth C. Anderson"]
[null,null,"Pubbl/distr/stampa",null,"[U.S.A.], : Bentham Science Publishers, [2012]"]
[null,null,"ISBN",null,"1-60805-297-4"]
[null,null,"Descrizione fisica",null,"1 online resource (217 p.)"]
[null,null,"Disciplina",null,"616.99/418"]
[{"$nulls":4},"616.99418"]
[null,null,"Soggetti",null,"Multiple myeloma - Treatment"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"section 1. Multiple myeloma -- section 2. Treatment guidelines -- section 3. The bone marrow microenvironment and the pathogenesis of multiple myeloma -- section 4. New treatment strategies."]
[null,null,null,"Sommario/riassunto","Multiple Myeloma (MM), the second most common blood cancer in adults, is a clonal plasma cell malignancy within the bone marrow characterized by osteolytic bone lesions, renal disease, and immunodeficiency. It is now well established that MM cell- induced disruption of the bone marrow homeostasis between the highly organized cellular and extracellular compartments supports MM cell proliferation, survival, migration, and drug resistance via activation of various signaling pathways. Based on this knowledge, the prototypic drugs thalidomide, bortezomib, and lenalidomide, which target both MM cell"]